Press Release

Shilpa Medicare Limited Corporate & Admin Office: “Shilpa House”, # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN: L85110KA1987PLC008739 Date: 24 June 2026 Corporate relationship Department, National Stock Exchange of India, Limited BSE Limited, Exchange Plaza, 5th Floor, 1st Floor, Rotunda Building Plot No. C/1, G Block, Bandra-Kurla Complex, P.J Towers Dalal Street, Fort, Bandra (E), Mumbai 400001 Mumbai 400051 Stock Code: BSE – 530549 / NSE – SHILPAMED Dear Sir/Ma’am, Sub: Press release on announcement of the commissioning of a state-of-the-art Antibody–Drug Conjugate (ADC) GMP Manufacturing Facility. Ref: under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ----------------------------------------------------------------------------------------------------------------------------------------------------- Please find enclosed a press release on announcement of commissioning of a state-of-art Antibody–Drug Conjugate (ADC) GMP Manufacturing Facility by Shilpa Biologicals Private Ltd, a material subsidiary of Shilpa Medicare Ltd. The above information is also available on the website of the Company www.vbshilpa.com For SHILPA MEDICARE LIMITED Ritu Tiwary Company Secretary & Compliance Officer Shilpa Medicare Limited Corporate & Admin Office: “Shilpa House”, # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN: L85110KA1987PLC008739 PRESS RELEASE Shilpa Biologicals Commissions One of India’s Very Few Integrated ADC Drug Substance GMP Manufacturing Facilities Dharwad, India — Shilpa Biologicals Ltd, a material subsidiary of Shilpa Medicare Ltd (NSE: SHILPAMED), today announced the commissioning of a state-of-the-art Antibody–Drug Conjugate (ADC) GMP Manufacturing Facility, purpose-built and designed to meet global regulatory approval standards including US FDA, EMA, and other major health authority requirements. The facility is fully operational, with GMP qualification protocols now actively underway, placing Shilpa on a clear path to commercial readiness. This commissioning marks a significant evolution of Shilpa Medicare’s over 25 years of deep-rooted expertise in highly potent compound manufacturing. Since its early years, Shilpa has built one of India’s most robust High Potency API (HPAPI) platforms — a discipline demanding the most exacting standards of containment, safety engineering, process rigour, and regulatory compliance. “The manufacturing of highly potent compounds has been a core pillar of Shilpa’s identity, and this ADC Drug Substance facility adds a new sophisticated dimension to the capabilities of the Shilpa group,” said Sridevi Khambhampaty, CEO, Shilpa Biologicals Pvt Ltd. “We now offer global biotech and pharma partners a uniquely integrated ADC facility built with the knowledge of our existing high potency manufacturing excellence.” With this commissioning, Shilpa Medicare Ltd becomes one of the very few companies in India to offer fully integrated, end-to-end ADC Drug Substance development and manufacturing — encompassing payload synthesis, linker development and manufacturing, monoclonal antibody production, ADC conjugation, and purification of GMP-scale Drug Substance. The manufacture of ADC Drug Substance demands specialised cytotoxic payload containment, precise conjugation chemistry, and rigorous biologic purification — all within a GMP- validated environment. This positions Shilpa as a compelling, cost-competitive CDMO partner for global pharmaceutical and biotech companies seeking high-quality, integrated ADC Drug Substance solutions. “India has the scientific talent and now, with this facility, the infrastructure as well to be a serious and trusted partner in global ADC Drug Substance manufacturing,” said Vishnukant Bhutada, Managing Director, Shilpa Medicare Ltd. “Our 25-year legacy in high potency manufacturing gives us a head start that very few can match. With the addition of this facility, we are able to provide comprehensive one stop solution to the world’s leading oncology innovators.” This commissioning reinforces Shilpa’s commitment to high-value biologics, complex oncology Drug Substance platforms, and innovation-driven GMP manufacturing. It is a decisive step in its long-term strategy to become a globally relevant CDMO partner for advanced oncology ADC Drug Substance manufacturing — contributing to differentiated, high-impact treatments for patients worldwide. Shilpa Medicare Limited Corporate & Admin Office: “Shilpa House”, # 12-6-214/A-1, Hyderabad Road, Raichur – 584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN: L85110KA1987PLC008739 About Shilpa Biologicals Ltd Shilpa Biologicals Ltd is a wholly owned subsidiary of Shilpa Medicare Ltd (NSE: SHILPAMED), focused on the development and contract manufacturing of complex biologics and oncology biologicals, with capabilities spanning early development through GMP-scale Drug Substance manufacturing. About Shilpa Medicare Ltd Shilpa Medicare Limited (BSE: 530549 | NSE: SHILPAMED) is a leading Indian pharmaceutical company focused on the development, manufacture, and marketing of APIs, formulations, and biologics across oncology, infectious diseases, and specialty segments. With expertise in complex generics, novel drug delivery systems, and CDMO services, Shilpa serves patients in over 80 countries. For more information, visit www.vbshilpa.com